ASB183X
Total Payments
$25,206
Transactions
11
Doctors
9
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $18,641 | 10 | 9 |
| 2017 | $6,565 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25,206 | 11 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL CONTINUATION STUDY OF THE ORAL AKT INHIBITOR GSK2110183 IN SUBJECTS WITH SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES | Novartis Pharmaceuticals Corporation | $16,277 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,929 | 9 |
Top Doctors Receiving Payments for ASB183X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $16,277 | 2 |
| Anthony Tolcher | Medical Oncology | San Antonio, TX | $992.11 | 1 |
| , MD MPH | Medical Oncology | Boston, MA | $992.11 | 1 |
| , M.D | Hematology & Oncology | Dallas, TX | $992.11 | 1 |
| , MD | Internal Medicine | Salt Lake City, UT | $992.11 | 1 |
| , M.D | Medical Oncology | Houston, TX | $992.11 | 1 |
| , M.D | Hematology & Oncology | Houston, TX | $992.11 | 1 |
| , MD | Medical Oncology | Aurora, CO | $992.11 | 1 |
| , MD | Hematology | Franklin, TN | $992.11 | 1 |
| , MD | Medical Oncology | Charlotte, NC | $992.11 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $25,206
- Total Doctors 9
- Transactions 11
About ASB183X
ASB183X is a drug associated with $25,206 in payments to 9 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $18,641 was paid across 10 transactions to 9 doctors.
The most common payment nature for ASB183X is "Unspecified" ($25,206, 100.0% of total).
ASB183X is associated with 2 research studies, including "AN OPEN LABEL CONTINUATION STUDY OF THE ORAL AKT INHIBITOR GSK2110183 IN SUBJECTS WITH SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES" ($16,277).